文献速递白血病

蛋白质组学优化急性髓系白血病治疗选择:维奈克拉联合低甲基化药物对比传统化疗

Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy.
PubMed 文献 · Leukemia · 2024-03-26

该研究利用反相蛋白阵列(RPPA)检测810例初诊成人急性髓系白血病(AML)患者411种蛋白表达,识别出109种预后蛋白并将患者分为五种表达谱,进而通过机器学习确定14种蛋白可准确推荐维奈克拉联合低甲基化药物(VH)或传统化疗(CC)。该策略预计使30%患者治疗改变,总生存(OS)改善43%,美国每年约增加2600例AML治愈。

要点

  • 411种蛋白中109种具预后价值,可将AML患者分为五种表达谱。
  • 机器学习筛选的14种蛋白可准确推荐VH或CC治疗。
  • 该蛋白质组学策略预计使30%患者治疗改变,OS改善43%。

核心结论

  • 基于RPPA的蛋白质组学分诊策略可优化AML患者VH与CC的选择,预计使30%患者治疗改变并带来43%的OS改善。

研究设计与样本

  • 研究纳入810例初诊成人AML患者,采用反相蛋白阵列(RPPA)检测411种蛋白表达,并结合机器学习算法进行分析。

主要发现

  • 在810例患者中识别出109种预后蛋白,并据此将患者分为五种表达谱。
  • 从109种蛋白中通过机器学习确定14种蛋白可准确推荐治疗。
  • 鉴定出一组对VH和CC均无获益的患者,并提出基于靶点的改善策略。
  • 计算显示该策略将使30%患者治疗改变,OS改善43%,美国每年约增加2600例AML治愈。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of Hypomethylating agents combined with Venetoclax (VH) for the treatment of Acute Myeloid Leukemia (AML) has greatly improved outcomes in recent years. However not all patients benefit from the VH regimen and a way to rationally select between VH and Conventional Chemotherapy (CC) for individual AML patients is needed. Here, we developed a proteomic-based triaging strategy using Reverse-phase Protein Arrays (RPPA) to optimize therapy selection. We evaluated the expression of 411 proteins in 810 newly diagnosed adult AML patients, identifying 109 prognostic proteins, that divided into five patient expression profiles, which are useful for optimizing therapy selection. Furthermore, using machine learning algorithms, we determined a set of 14 proteins, among those 109, that were able to accurately recommend therapy, making it feasible for clinical application. Next, we identified a group of patients who did not benefit from either VH or CC and proposed target-based approaches to improve outcomes. Finally, we calculated that the clinical use of our proteomic strategy would have led to a change in therapy for 30% of patients, resulting in a 43% improvement in OS, resulting in around 2600 more cures from AML per year in the United States.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. de Camargo Magalhães ES, Hubner SE, Brown BD, et al. Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy. Leukemia. 2024. PMID: 38531950. doi:10.1038/s41375-024-02208-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。